Cholesterol and Lipoprotien Particle Profile (LPP+)

Recent research indicates an increased risk of dementia in patients with long term use of statin medications for lowering cholesterol. This is frightening, especially when we consider that this is the most often and profitable prescribed medication. In other words, it will take years, to get patients to stop taking them, and years before doctors stop prescribing. The true risk of cholesterol needs to be  addressed and alternative or natural therapies applied before running any further risk of other serious illnesses.

LLP+™ is an extensive specialty blood test, performed at Spectracell Laboratories that determines the size and presence of lipoproteins such as LDL, HDL, RLP, and Lipoprotein (a). The size of the LDL and HDL particles are more valuable measures of risk than the total number measured. The smaller the size of the LDL, the more likely it will invade the arterial wall and increase plaque formation. The LPP+™ plus evaluates the presence of LDL III and LDL IV, the smallest LDL particles, to determine if they are contributing to atherosclerosis. This is not accounted for on the standard cholesterol panel.

The LLP+™ measures another important marker, Lipoprotein (a), which is a direct cause of plaque growth and plaque rupture that can lead to a heart attack. RLP is considered to be one of the most harmful lipoproteins. Elevated RLP has been found in survivors of heart attacks.  These again are not assessed using the standard cholesterol tests. Other tests included in the panel, which are helpful to evaluate risk and determine treatment, include C-reactive Protein(CRP), Homocysteine, and Insulin.

Evaluation of cholesterol by advanced lipoprotein profiles is helpful in determining absolute need for cholesterol medication. Natural therapies exist to lower and reduce CVD risk, without side effects or future risk.